Richard Ceska

List of Publications by Citations

96 papers	5,916 citations	27 h-index	76 g-index
141 ext. papers	6,722 ext. citations	5.8 avg, IF	5.01 L-index

#	Paper	IF	Citations
96	Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *New England Journal of Medicine*, **2015**, 372, 1489-99	59.2	1347
95	A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *New England Journal of Medicine*, **2014**, 370, 1809-19	59.2	506
94	Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1870-82	27.4	347
93	Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. *Diabetes Care*, **2012**, 35, 1232-8	14.6	339
92	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *European Heart Journal*, **2015**, 36, 2996-3003	9.5	311
91	Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1580-90	27.4	307
90	The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia. *American Journal of Cardiology*, **2008**, 102, 1K-34K	3	280
89	Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. *Journal of Clinical Investigation*, **2000**, 106, 1263-70	15.9	266
88	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Archives of Medical Science*, **2015**, 11, 1-23	2.9	252
87	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. *Diabetes and Vascular Disease Research*, **2008**, 5, 319-35	3.3	192
86	Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. *PLoS ONE*, **2012**, 7, e49006	3.7	165
85	Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. *American Journal of Cardiology*, **1998**, 81, 912-7	3	158
84	Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT). *Cardiovascular Research*, **2001**, 52, 290-8	9.9	112
83	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Expert Opinion on Drug Safety*, **2015**, 14, 935-55	4.1	94
82	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 455-63	18.1	68
81	Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. *Psychiatry Research*, **2005**, 133, 197-203	9.9	67
80	The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM)paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. *Cardiovascular Diabetology*, **2019**, 18, 71	8.7	64

79	The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. *Atherosclerosis Supplements*, **2014**, 15, 1-15	1.7	62
78	Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy. *Nutrition*, **2001**, 17, 721-3	4.8	49
77	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. *American Heart Journal*, **2002**, 144, E6	4.9	46
76	Drug-drug interactions with statins: will pitavastatin overcome the statinsSAchillesSheel?. *Current Medical Research and Opinion*, **2011**, 27, 1551-62	2.5	41
75	Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. *Annals of Medicine*, **2010**, 42, 447-64	1.5	40
74	T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. *Atherosclerosis*, **2003**, 167, 369-70	3.1	40
73	Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. *Metabolism: Clinical and Experimental*, **2008**, 57, 1088-92	12.7	39
72	Statin Intolerance: the ClinicianS Perspective. *Current Atherosclerosis Reports*, **2015**, 17, 69	6	38
71	Statin-associated myopathy: from genetic predisposition to clinical management. *Physiological Research*, **2014**, 63, S327-34	2.1	37
70	Impact of apolipoprotein A5 variants on statin treatment efficacy. *Pharmacogenomics*, **2009**, 10, 945-50	2.6	30
69	FTO and MC4R gene variants determine BMI changes in children after intensive lifestyle intervention. *Clinical Biochemistry*, **2013**, 46, 313-6	3.5	27
68	Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes. *European Journal of Pharmacology*, **2004**, 493, 183-9	5.3	26
67	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. *JAMA Cardiology*, **2020**, 5, 709-713	16.2	25
66	Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial. *Clinical Cardiology*, **2016**, 39, 137-44	3.3	25
65	MLXIPL variant in individuals with low and high triglyceridemia in white population in Central Europe. *Human Genetics*, **2008**, 124, 553-5	6.3	25
64	Serum leptin levels in patients with hyperlipidemias. *Nutrition*, **2000**, 16, 429-33	4.8	25
63	Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia. *American Journal of Cardiology*, **2003**, 92, 337-41	3	24
62	Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. *International Journal of Clinical Practice*, **2010**, 64, 727-38	2.9	23

61	SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. *Medical Science Monitor*, **2015**, 21, 1454-9	3.2	22
60	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. *American Heart Journal*, **2003**, 146, E21	4.9	20
59	Ser19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. *Journal of Medical Genetics*, **2003**, 40, e105	5.8	20
58	Treatment of hypertriglyceridemia: a review of current options. *Physiological Research*, **2015**, 64, S331-40	2.1	18
57	Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine. *American Heart Journal*, **2003**, 146, 110	4.9	17
56	Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. *Physiological Research*, **2003**, 52, 439-45	2.1	17
55	Impact of variants within seven candidate genes on statin treatment efficacy. *Physiological Research*, **2012**, 61, 609-17	2.1	16
54	Hypertriglyceridemia: interaction between APOE and APOAV variants. *Clinical Chemistry*, **2005**, 51, 1311-5	5.5	13
53	Familial hypercholesterolemia in the Czech Republic: more than 17 years of systematic screening within the MedPed project. *Physiological Research*, **2017**, 66, S1-S9	2.1	12
52	Ivabradine in stable coronary artery disease. *New England Journal of Medicine*, **2014**, 371, 2435	59.2	11
51	Clinical implications of the metabolic syndrome. *Diabetes and Vascular Disease Research*, **2007**, 4 Suppl 3, S2-4	3.3	11
50	Detection of variability in apo(a) gene transcription regulatory sequences using the DGGE method. *Clinica Chimica Acta*, **2007**, 376, 77-81	6.2	11
49	Gene variants at FTO, 9p21, and 2q36.3 are age-independently associated with myocardial infarction in Czech men. *Clinica Chimica Acta*, **2016**, 454, 119-23	6.2	10
48	APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels. *Clinical Chemistry and Laboratory Medicine*, **2008**, 46, 773-7	5.9	10
47	Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. *American Heart Journal*, **2002**, 144, G1-G8	4.9	10
46	Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. *Physiological Research*, **2008**, 57, 919-925	2.1	10
45	The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. *Current Atherosclerosis Reports*, **2019**, 21, 36	6	9
44	Association between polymorphism within the RYR2 receptor and development of statin-associated myalgia/myopathy in the Czech population. *European Journal of Internal Medicine*, **2015**, 26, 367-8	3.9	8

43	A comprehensive guidelines-based approach reduces cardiovascular risk in everyday practice: the VARO study. *Archives of Medical Science*, **2017**, 13, 705-710	2.9	8
42	Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia. *Atherosclerosis*, **2003**, 166, 197-8	3.1	8
41	Apoe genotype is not associated with variations in bone mineral density. *Atherosclerosis*, **1999**, 144, 103-104	3.1	8
40	Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). *Pharmacological Research*, **2020**, 155, 104719	10.2	7
39	Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes. *Atherosclerosis*, **2005**, 183, 367-8	3.1	7
38	Increase of inflammatory state in overweight adults with combined hyperlipidemia. *Nutrition, Metabolism and Cardiovascular Diseases*, **2003**, 13, 227-31	4.5	7
37	The Gene Score for Predicting Hypertriglyceridemia: New Insights from a Czech Case-Control Study. *Molecular Diagnosis and Therapy*, **2019**, 23, 555-562	4.5	6
36	Nitroglycerin induced syncope occurs in subjects with delayed phase shift of baroreflex action. *PACE - Pacing and Clinical Electrophysiology*, **2002**, 25, 828-32	1.6	6
35	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. *Atherosclerosis*, **2003**, 166, 195-6	3.1	6
34	Apolipoprotein AV gene polymorphisms (T-1131/C and Ser19/Trp) influence plasma triglyceride levels and risk of myocardial infarction. *Experimental and Clinical Cardiology*, **2003**, 8, 151-4		6
33	The Impact of Physical Activity and Dietary Measures on the Biochemical and Anthropometric Parameters in Obese Children. Is There Any Genetic Predisposition?. *Central European Journal of Public Health*, **2015**, 23 Suppl, S62-6	1.2	6
32	ScreenPro FH: from the Czech MedPed to international collaboration. ScreenPro FH is a participating project of the EAS-FHCS. *Physiological Research*, **2017**, 66, S85-S90	2.1	6
31	Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy. *Neuroendocrinology Letters*, **2012**, 33 Suppl 2, 22-5	0.3	6
30	Rosiglitazone influences the expression of leukocyte adhesion molecules and CD14 receptor in type 2 diabetes mellitus patients. *Physiological Research*, **2014**, 63, S293-8	2.1	5
29	Statins, glycemia, and diabetes mellitus: another point of view. *Current Atherosclerosis Reports*, **2014**, 16, 458	6	4
28	Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy. *Journal of Applied Biomedicine*, **2012**, 10, 19-28	0.6	4
27	Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: data from the MedPed CZ database and the Czech population. *Clinica Chimica Acta*, **2011**, 412, 920-4	6.2	4
26	The apo(a) gene (TTTTA)n promoter polymorphism and its association with variability in exons of the kringle IV types 8 to 10. *Clinica Chimica Acta*, **2009**, 405, 39-42	6.2	4

25	Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report. *Journal of Internal Medicine*, **1999**, 246, 235-6	10.8	4
24	Body Adiposity Changes After Lifestyle Interventions in Children/Adolescents and the NYD-SP18 and TMEM18 Variants. *Medical Science Monitor*, **2018**, 24, 7493-7498	3.2	4
23	Statin Intolerance in Clinical Practice. *Current Atherosclerosis Reports*, **2020**, 22, 27	6	3
22	APOA5 haplotypes determine triglyceride decrease after lifestyle induced weight loss in children. *Nutrition, Metabolism and Cardiovascular Diseases*, **2012**, 22, e22-3	4.5	3
21	Interaction of common sequence variants and selected risk factors in determination of HDL cholesterol levels. *Clinical Biochemistry*, **2010**, 43, 754-8	3.5	3
20	Decreasing common carotid artery intimal thickness during hypolipidemic therapy. *Angiology*, **1997**, 48, 761-7	2.1	3
19	Variability in apo(a) gene regulatory sequences, compound genotypes, and association with Lp(a) plasma levels. *Clinical Biochemistry*, **2007**, 40, 802-5	3.5	3
18	Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). *Journal of Cachexia, Sarcopenia and Muscle*,	10.3	3
17	Combined therapy of mixed dyslipidemia in patients with high cardiovascular risk and changes in the lipid target values and atherogenic index of plasma. *Cor Et Vasa*, **2014**, 56, e133-e139	0.3	2
16	Ivabradine, coronary heart disease, and heart failure: time for reappraisal. *Current Atherosclerosis Reports*, **2014**, 16, 463	6	2
15	IMPACT OF APOLIPOPROTEIN A5 GENE VARIANTS ON STATIN TREATMENT EFFICACY. *Atherosclerosis Supplements*, **2008**, 9, 40	1.7	2
14	Type III hyperlipoproteinaemia and primary amenorrhoea associated with severe hypothyroidism. *Acta Paediatrica, International Journal of Paediatrics*, **2007**, 89, 1023-1024	3.1	2
13	Hypolipidemic drugs, blood pressure, heart rate, heart rate variability and sympathetic activity. *International Congress Series*, **2004**, 1262, 458-461		2
12	Strong Association between APOA5 Gene Polymorphisms and Hypertriglyceridaemic Episodes. *Folia Biologica*, **2019**, 65, 188-194	0.7	2
11	Prevention of diabetes with rosiglitazone: Evidence of benefit or unexpected harm?. *Medical Hypotheses*, **2008**, 70, 199-200	3.8	1
10	Folic acid does not improve surrogate markers of early atherosclerosis in atorvastatin-treated patients. *Nutrition Research*, **2007**, 27, 181-185	4	1
9	Flow-dependent vasomotor dysfunction of the popliteal artery related to common carotid artery intima-media thickness. *Angiology*, **2001**, 52, 689-95	2.1	1
8	Implementation of cardiovascular disease prevention guidelines into clinical practice: an unmet challenge?. *Current Pharmaceutical Design*, **2015**, 21, 1180-4	3.3	1

7	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part I: Genetics and Biochemical Parameters.. *Frontiers in Genetics*, **2022**, 13, 849008	4.5	1
6	Familial Hypercholesterolemia: Real-World Data of 1236 Patients Attending a Czech Lipid Clinic. A Retrospective Analysis of Experience in More than 50 years. Part II. Clinical Characteristics.. *Frontiers in Genetics*, **2022**, 13, 849267	4.5	1
5	PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology.. *Current Atherosclerosis Reports*, **2022**, 1	6	1
4	Statin therapy is a major determinant of PCSK9 plasma concentration: data from four clinical trials with AMG 145. *European Heart Journal*, **2013**, 34, P681-P681	9.5	
3	Is it safe to combine PPAR agonists? A lesson from muraglitazar. *Medical Hypotheses*, **2006**, 67, 669	3.8	
2	New strategies in the treatment of dyslipidemia: do we know how?. *Seminars in Vascular Medicine*, **2004**, 4, 305-10		
1	Comments on the most important and recent studies involving PCSK9i. *Vnitrni Lekarstvi*, **2018**, 64, 1137-1141	0.5	